Genetic testing considerations for hereditary duodenopancreatic neuroendocrine tumors
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 02.11.2026. Verfasst von Théo Charnay und 13 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa Institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseil…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Genetic Testing, Duodenal Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Initiative d'Excellence d'Aix-Marseille Université - A*MIDEX.
Abstract (Originalsprache)
The incidence of duodenal and pancreatic neuroendocrine tumors (dpNETs) has increased substantially in recent years. These tumors may be due to syndromic hereditary predisposition syndromes: multiple endocrine neoplasia type 1 (MEN1) or 4 (MEN4), Von Hippel–Lindau disease (VHL), neurofibromatosis type 1 (NF1), or tuberous sclerosis complex (TSC). Because a dpNET may be the first MEN1 sign, recent guidelines recommend MEN1 genetic testing in selected patients with an isolated dpNET. Whether similar genetic testing strategies should be extended to other hereditary syndromes remains unknown. We conducted a retrospective analysis of the genetic and clinical data of patients who underwent genetic testing for isolated or syndromic dpNETs. We assessed the presence of (likely) pathogenic variants ((L)PVs) in MEN1 , NF1 , VHL , CDKN1B , TSC1 , and TSC2 . 410 patients were included: 301 with isolated (=non syndromic) dpNETs and 109 with syndromic dpNETs. Among them, 38 carried a (L)PV, most frequently in MEN1 ( n = 27 patients), followed by NF1 ( n = 8) and VHL ( n = 3). No TSC1 , TSC2 , or CDKN1B (L)PVs were found. Patients with syndromic dpNETs exhibited significantly higher positive rates (29.4%) compared to isolated dpNETs (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille Univ, APHM, INSERM, MMG, MarMaRa Institute, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, BIOGENOPOLE, Marseille, France.
- APHM, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, Marseille, France.
- Aix Marseille Univ, APHM, Inserm, MMG, MarMaRa Institute, La Conception University Hospital, Department of Endocrinology, Marseille, France.
- Haut Leveque University Hospital, Department of Endocrinology, Bordeaux, France.
- Institut Paoli Calmettes, Medical Oncology Department, IPCNET Center, ENETS Center of Excellence, Marseille, France.
- Oncogenetique Department Institut Antoine Lacassagne, Nice, France.
ORCID-Profile: Théo Charnay, Sandrine Oziel-Taieb, Veronique Mari, Olivier Gilly, Isabelle Raingeard, Alexandre Astier, Thomas Cuny, Pauline Romanet, Anne Barlier
Förderung
- Initiative d'Excellence d'Aix-Marseille Université - A*MIDEX
Zitieren
APA
Charnay, T., Giannetti, C., Sahakian, N., Haissaguerre, M., Oziel-Taieb, S., Mari, V., Gilly, O., Vital, P., Raingeard, I., Découdier, B., Astier, A., Cuny, T., Romanet, P., & Barlier, A. (2026). Genetic testing considerations for hereditary duodenopancreatic neuroendocrine tumors. Journal of Neuroendocrinology, 38(11). https://doi.org/10.1111/jne.70305
Vancouver
Charnay T, Giannetti C, Sahakian N, Haissaguerre M, Oziel-Taieb S, Mari V, et al. Genetic testing considerations for hereditary duodenopancreatic neuroendocrine tumors. Journal of Neuroendocrinology. 2026;38(11). doi:10.1111/jne.70305
BibTeX
@article{Charnay2026,
author = {Charnay, Théo and Giannetti, Camille and Sahakian, Nicolas and Haissaguerre, Magalie and Oziel-Taieb, Sandrine and Mari, Veronique and Gilly, Olivier and Vital, Pauline and Raingeard, Isabelle and Découdier, Bénédicte and Astier, Alexandre and Cuny, Thomas and Romanet, Pauline and Barlier, Anne},
title = {Genetic testing considerations for hereditary duodenopancreatic neuroendocrine tumors},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {11},
doi = {10.1111/jne.70305}
}
EUVIMED